

Puma Biotechnology Medical Director Dr Brian Barnett

Patients whose adverse affects are appropriately managed and remain on NERLYNX for longer stand to gain the most benefit. That was the top-line message from a further analysis of the pivotal phase 3 ExteNET study, according to Puma Biotechnology Medical Director Dr Brian Barnett at ASCO 2018.

Here he discusses the CONTROL study and optimal strategies for mitigating adverse events associated with NERLYNX.

Watch the interview by clicking the link below.

